SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 6, 2013--
Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey,
Ph.D., the company’s president and chief executive officer, will present
at the 15th Annual BIO CEO & Investor Conference at 8:30 a.m.
EST / 5:30 a.m. PST on Tuesday, February 12, 2013, in New York. During
the presentation, Dr. Morrissey will review the company’s development
plans and priorities for cabozantinib in 2013. He will also discuss the
company’s corporate strategy and financial outlook, and provide a
general business update.
The presentation will be webcast and may be accessed via the Event
Calendar page under Investors & Media at www.exelixis.com.
About Exelixis
Exelixis, Inc. is a biotechnology company committed to developing small
molecule therapies for the treatment of cancer. Exelixis is focusing its
proprietary resources and development efforts exclusively on COMETRIQ™
(cabozantinib). Exelixis has also established a portfolio of other novel
compounds that it believes have the potential to address serious unmet
medical needs, many of which are being advanced by partners as part of
collaborations. For more information, please visit the company's web
site at www.exelixis.com.
Source: Exelixis, Inc.
Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President,
Investor
Relations and
Corporate Communications
cbutler@exelixis.com
